Viracta Therapeutics, Inc. VIRX
We take great care to ensure that the data presented and summarized in this overview for Viracta Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VIRX
View all-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.52MShares$349,6550.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA954KShares$219,5310.0% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA690KShares$158,6330.09% of portfolio
-
Stonepine Capital Management, LLC Bend, OR500KShares$115,0000.07% of portfolio
-
Laurion Capital Management LP New York, NY332KShares$76,4030.0% of portfolio
-
Aisling Capital Management LP New York, NY289KShares$66,3710.03% of portfolio
-
Black Rock Inc. New York, NY273KShares$62,8580.0% of portfolio
-
Geode Capital Management, LLC Boston, MA250KShares$57,5010.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny245KShares$56,4410.0% of portfolio
-
Hrt Financial LP New York, NY139KShares$31,9290.0% of portfolio
Latest Institutional Activity in VIRX
Top Purchases
Top Sells
About VIRX
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510 (formerly SNS-510), a preclinical-stage PDK-1 inhibitor. It is evaluating development and collaboration opportunities for vecabrutinib in combination with chimeric antigen receptor T-cell therapies and VRx-510 in various oncology indications. The company was formerly known as Sunesis Pharmaceuticals, Inc. to Viracta Therapeutics, Inc. in February 25, 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.
Insider Transactions at VIRX
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Nov 25
2024
|
Roger Pomerantz |
BUY
Exercise of conversion of derivative security
|
Direct |
9,034
+6.67%
|
-
|
Nov 25
2024
|
Ivor Royston |
BUY
Exercise of conversion of derivative security
|
Direct |
25,219
+2.92%
|
-
|
Aug 25
2024
|
Roger Pomerantz |
BUY
Exercise of conversion of derivative security
|
Direct |
9,034
+7.14%
|
-
|
Aug 25
2024
|
Ivor Royston |
BUY
Exercise of conversion of derivative security
|
Direct |
25,219
+3.0%
|
-
|
May 25
2024
|
Roger Pomerantz |
BUY
Exercise of conversion of derivative security
|
Direct |
9,035
+7.69%
|
-
|
May 25
2024
|
Ivor Royston |
BUY
Exercise of conversion of derivative security
|
Direct |
25,219
+3.1%
|
-
|
Feb 27
2024
|
Daniel R. Chevallard CFO and COO |
SELL
Open market or private sale
|
Direct |
3,405
-3.22%
|
$0
$0.73 P/Share
|
Feb 25
2024
|
Roger Pomerantz |
BUY
Exercise of conversion of derivative security
|
Direct |
9,034
+8.33%
|
-
|
Feb 25
2024
|
Ivor Royston |
BUY
Exercise of conversion of derivative security
|
Direct |
25,219
+3.2%
|
-
|
Feb 25
2024
|
Daniel R. Chevallard CFO and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,889
+6.12%
|
-
|
Dec 01
2023
|
Mark Rothera President and CEO |
BUY
Open market or private purchase
|
Direct |
47,906
+32.39%
|
$0
$0.49 P/Share
|
Nov 30
2023
|
Mark Rothera President and CEO |
BUY
Open market or private purchase
|
Direct |
52,094
+50.0%
|
$0
$0.49 P/Share
|
Nov 28
2023
|
Daniel R. Chevallard CFO and COO |
SELL
Open market or private sale
|
Direct |
3,720
-3.63%
|
$0
$0.5 P/Share
|
Nov 25
2023
|
Daniel R. Chevallard CFO and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,889
+6.3%
|
-
|
Nov 25
2023
|
Roger Pomerantz |
BUY
Exercise of conversion of derivative security
|
Direct |
9,034
+9.09%
|
-
|
Nov 25
2023
|
Ivor Royston |
BUY
Exercise of conversion of derivative security
|
Direct |
25,219
+3.3%
|
-
|
Aug 28
2023
|
Daniel R. Chevallard CFO and COO |
SELL
Open market or private sale
|
Direct |
3,512
-3.54%
|
$3,512
$1.45 P/Share
|
Aug 25
2023
|
Roger Pomerantz |
BUY
Exercise of conversion of derivative security
|
Direct |
9,034
+10.0%
|
-
|
Aug 25
2023
|
Ivor Royston |
BUY
Exercise of conversion of derivative security
|
Direct |
25,219
+3.41%
|
-
|
Aug 25
2023
|
Daniel R. Chevallard CFO and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,888
+6.49%
|
-
|
Last 12 Months Summary
Exercise of conversion of derivative security | 144K shares |
---|
Open market or private sale | 3.41K shares |
---|